Raj Alva

Asana BioSciences, a clinical-stage biopharmaceutical company, was founded in 2014 with the mission to develop novel, clinically differentiated, best-in-class products that address unmet medical needs and provide new treatment options for cancer patients and those suffering from inflammatory conditions. Seven successful INDs were filed in a short span after founding of Asana and multiple clinical proof of concepts studies have been completed in oncology and immunology/inflammation therapeutic categories. Gusacitinib (ASN002), Asana’s lead immunology asset, is entering phase 3 development. Asana’s lead oncology asset (ASN007 or ERAS-007) has completed phase 1 trials in cancer patients. Multiple drugs from Asana’s portfolio have already been out-licensed/partnered with other biotech companies for further development and commercialization.

Kashiv BioSciences, LLC is a fully integrated biosciences company headquartered in Bridgewater, New Jersey with locations in Piscataway, NJ, Chicago IL, and Ahmedabad, India. Kashiv BioSciences’ broad business offering includes drug delivery platforms incorporating delayed release technology and gastric retention systems that improve the efficacy and safety of known drugs, a 505(b)(2) pipeline of development products targeting unmet clinical needs, biosimilars and prodrugs. Additionally, as part of a development collaboration Kashiv BioSciences has approved generic products and products in advanced stages of development, including several complex generic products. Kashiv BioSciences’ medications will improve the lives of patients suffering from cancer as well as neuromuscular, movement and endocrine disorders, among other debilitating conditions, both in the U.S. and globally. The combined breadth of expertise in small and large molecules, peptides, proteins and monoclonal antibodies enables Kashiv BioSciences to develop products with meaningful clinical differentiation and a compelling value proposition for patients, physicians and payers.

Aidéo Technologies is a leading provider of medical coding productivity solutions to the revenue cycle management industry. Creating scalable and repeatable coding efficiency, Aidéo Technologies’ Gemini Solution Suite empowers and compliments medical coders with workflow efficiencies, artificial intelligence, and supplemental coding services. The Gemini Coder Platform™, Gemini AutoCode™, and Gemini Coding Assist™ solutions are optimized to work together for maximum impact in creating efficiency and improving accuracy through workflow improvements and autonomous and predictive coding. Aidéo is headquartered in West Palm Beach, FL with locations in the San Francisco Bay area and Mumbai, India.

Greyson was founded by Charlie Schaefer, the previous SVP of design at Ralph Lauren. After 13 years of design experience from Ralph Lauren, Charlie parted ways to take on his biggest dream – the creation of his own label. Inspirited with the concept of creation, freedom & excellence. Greyson - Juxtaposing fashion and sport as it proves to be a sustainable trend through fitness, wellness and health. Surpassing the pack, passion and vision drive the team to create products suitable for a fashion-forward yet functional lifestyle.

Founded by CMA Entertainer of the Year and 10-time GRAMMY nominee Eric Church and entrepreneur Raj Alva in 2020 as a purpose-driven creative incubator for whiskey innovation. After three years of research and development into creating and curating the finest possible whiskey products, processes, team, and partnerships, the company officially launched its first of many planned whiskey releases, Whiskey JYPSI’s Legacy Batch 001, in June 2023. This whiskey recently received the coveted Double Gold Medal from the San Francisco World Spirits Competition – awarded to only the finest products in the world. Categorizing whiskeys by “mash bill”, or the percentage of each type of grain, has become a shorthand way of indicating the style and character of the finished liquid inside the bottle. Legacy took that shorthand and used cross-category blending to reconstruct the traditional mash bill with single grain whiskey’s that were separately aged - without consideration for regional or national boundaries. This allowed us to select from a wider portfolio of international whiskeys - and to ensure that each whiskey is at the exact right age and flavor profile to perfectly harmonize this particular blend. We call it Whiskey JYPSI to celebrate those who think differently, reinvent the rules and seek greater adventure and purpose in life. Those who live life with a “JYPSI Spirit.” After all, it was this philosophy that inspired us to turn a celebrity brand on its head, and use it as a platform to promote innovation and creativity. Not just to showcase another star. As a result, Whiskey JYPSI has taken the extraordinary step of securing a proprietary “library” of various whiskeys from around the world. Enough to continue our series of limited-quantity releases for the next decade. And each batch of our Legacy Series whiskey will be unique in its sourcing, blending and finishing approach. When one batch is sold out, it will not be replicated.

Asana BioSciences, a clinical-stage biopharmaceutical company, was founded in 2014 with the mission to develop novel, clinically differentiated, best-in-class products that address unmet medical needs and provide new treatment options for cancer patients and those suffering from inflammatory conditions. Seven successful INDs were filed in a short span after founding of Asana and multiple clinical proof of concepts studies have been completed in oncology and immunology/inflammation therapeutic categories. Gusacitinib (ASN002), Asana’s lead immunology asset, is entering phase 3 development. Asana’s lead oncology asset (ASN007 or ERAS-007) has completed phase 1 trials in cancer patients. Multiple drugs from Asana’s portfolio have already been out-licensed/partnered with other biotech companies for further development and commercialization.

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and significant mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases. - The companys lead product, SANGUINATE™, is focused on treating the comorbidities of sickle cell disease and hemorrhagic stroke - Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy - Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer ___________

Kashiv BioSciences, LLC is a fully integrated biosciences company headquartered in Bridgewater, New Jersey with locations in Piscataway, NJ, Chicago IL, and Ahmedabad, India. Kashiv BioSciences’ broad business offering includes drug delivery platforms incorporating delayed release technology and gastric retention systems that improve the efficacy and safety of known drugs, a 505(b)(2) pipeline of development products targeting unmet clinical needs, biosimilars and prodrugs. Additionally, as part of a development collaboration Kashiv BioSciences has approved generic products and products in advanced stages of development, including several complex generic products. Kashiv BioSciences’ medications will improve the lives of patients suffering from cancer as well as neuromuscular, movement and endocrine disorders, among other debilitating conditions, both in the U.S. and globally. The combined breadth of expertise in small and large molecules, peptides, proteins and monoclonal antibodies enables Kashiv BioSciences to develop products with meaningful clinical differentiation and a compelling value proposition for patients, physicians and payers.

New Mountain Capital (“New Mountain”) is an alternative investment manager with private equity, credit and net lease strategies. New Mountain’s aggregate assets under management total ~$50 billion across all investment strategies.* Since inception, New Mountain has raised over $27 billion of committed capital across six private equity funds. New Mountain was founded in 1999 by Steven B. Klinsky and today has ~245 employees, ~145 of which are investment professionals. New Mountain’s efforts emphasize intensive fundamental research and a focus on growth and investor “value added,” rather than reliance on excessive risk, as the best path to high and consistent long-term returns. New Mountain has proactively developed particular research and operational expertise in carefully selected “defensive growth” niches of healthcare, health tech, life science supplies/biomanufacturing, “must have” information and data, digital marketing & transformation, infrastructure services/field services, specialized software, defensive growth consumer/products, financial services / technologies and technology-enabled business services. New Mountain Capital works systematically to establish expertise in additional sectors over time. * Includes asset valuations and remaining commitments (if applicable) as of December 31, 2023 and undrawn capital as of December 31, 2023. Pro forma for capital committed as of April 1, 2024)